<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02156388</url>
  </required_header>
  <id_info>
    <org_study_id>Tmab-GW003-NP-01</org_study_id>
    <nct_id>NCT02156388</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors</brief_title>
  <official_title>A Single-center, Uncontrolled, Open, Phase 1 Study of Recombinant(Expressed by Pichia Pastoris) Human Serum Albumin/Human Granulocyte-Colony Stimulating Factor(I)Fusion Protein For Injection(GW003)to Metastatic Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu T-Mab Biopharma Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu T-Mab Biopharma Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to access the safety, tolerance and&#xD;
      Pharmacokinetic/Pharmacodynamic(PK/PD) of single subcutaneous(SC) injection of GW003 in&#xD;
      patients with metastatic tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      So far, granulocyte colony stimulating factor (G-CSF) is still currently the only effective&#xD;
      and security therapy drug for neutropenia caused by cancer chemotherapy. At present, the&#xD;
      widely used G-CSF products are of such short-acting G-CSF product in China. However, there&#xD;
      existed some shortcoming about short-acting G-CSF, such as shorter half-life, continuous&#xD;
      monitoring of the patient's blood neutrophil count and so on.&#xD;
&#xD;
      Nowadays,long-acting G-CSF product,such as Neulasta®, has become the mainstream of the&#xD;
      foreign G-CSF market for its superiority of long half-life and absence of monitoring of the&#xD;
      patient's blood neutrophil count. The new drug Recombinant(Expressed by Pichia pastoris)&#xD;
      Human Serum Albumin/Human Granulocyte-Colony Stimulating Factor(I)Fusion Protein(GW003) is a&#xD;
      long-acting G-CSF.Preclinical studies have shown that GW003 has accelerated neutrophil&#xD;
      recovery and can shorten the duration of neutropenia symptoms, also reduce its extent,&#xD;
      therefore minimize the likelihood of serious infections, reflecting a better efficacy and&#xD;
      more long half-life.&#xD;
&#xD;
      Phase I was performed as two parts, Ia and Ib. Ia was a sequential dose escalation to observe&#xD;
      the dose-limiting toxicity(DLT) and Maximum Tolerated Dose of GW003 given subcutaneously to&#xD;
      patients without receiving chemotherapy,6 dose cohorts(50、150、300、400、500 and 600μg/kg) with&#xD;
      2-3 subjects in the 50、150μg/kg cohorts and 3-6 subjects（depend on the Dose-limiting&#xD;
      toxicity） in the 300、400、500 and 600μg/kg cohorts, to evaluate safety and pharmacokinetics&#xD;
      prior to the Ⅰb.&#xD;
&#xD;
      Ib proposed two arms (150 and 300μg/kg；n=6-8/arm), and to determine whether to continue to&#xD;
      increase other dose arm based on the safety and efficacy assessment. Subjects need to receive&#xD;
      two cycles treatment of AT chemotherapy. In cycle 1, subjects received AT chemotherapy only;&#xD;
      in cycle 2, subjects were administered subcutaneously GW003 24 hours after chemotherapy&#xD;
      drugs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse event</measure>
    <time_frame>Ia:up to 4weeks;Ib: up to 10weeks</time_frame>
    <description>To evaluate the safety and tolerance of single SC injection of GW003 to Metastatic Tumors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of severe neutropenia(DSN)</measure>
    <time_frame>Ia: up to 3weeks;Ib: up to 6weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-GW003 antibody</measure>
    <time_frame>Ia: up to 28weeks;Ib: up to 34weeks.</time_frame>
    <description>Ia:anti-GW003 antibody was detected pre-dose and when visit,if there exist positive anti-GW003 antibody, another detected should be conducted 6 months after the trial.&#xD;
Ib:anti-GW003 antibody was detected pre-dose ,after cycle 2 chemotherapy and when visit,if there exist positive anti-GW003 antibody, another detected should be conducted 6 months after the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>half-life(consists of distribution half-life [t1/2α] and elimination half-life [t1/2β])</measure>
    <time_frame>Pre-dose、0.5h、1h、2h、3h、6h、9h、12h、24h、48h、72h、96h、120h、144h and 168h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the concentration-time curve (AUC)</measure>
    <time_frame>Pre-dose、0.5h、1h、2h、3h、6h、9h、12h、24h、48h、72h、96h、120h、144h and 168h post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Chemotherapy-induced Neutropenia</condition>
  <condition>Metastatic Tumors</condition>
  <arm_group>
    <arm_group_label>Ia-GW003 50μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-3 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ia-GW003 150μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-3 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ia-GW003 300μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-6 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ia-GW003 400μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-6 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ia-GW003 500μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-6 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ia-GW003 600μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-6 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ib-GW003 150μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6-8 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ib-GW003 300μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6-8 subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GW003</intervention_name>
    <description>freeze-dried powder；single SC injection</description>
    <arm_group_label>Ia-GW003 150μg/kg</arm_group_label>
    <arm_group_label>Ia-GW003 300μg/kg</arm_group_label>
    <arm_group_label>Ia-GW003 400μg/kg</arm_group_label>
    <arm_group_label>Ia-GW003 500μg/kg</arm_group_label>
    <arm_group_label>Ia-GW003 50μg/kg</arm_group_label>
    <arm_group_label>Ia-GW003 600μg/kg</arm_group_label>
    <arm_group_label>Ib-GW003 150μg/kg</arm_group_label>
    <arm_group_label>Ib-GW003 300μg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with pathologically and/or cytologically-confirmed malignant tumor (phase Ia)&#xD;
&#xD;
          2. Breast-cancer or NSCLC patients are suitable for chemotherapy regimen of receiving&#xD;
             docetaxel plus adriamycin and could finish two-cycles adjuvant chemotherapy on&#xD;
             schedule&#xD;
&#xD;
          3. 18 years to 65years&#xD;
&#xD;
          4. Patients with Eastern Cooperative Oncology Group(ECOG) performance status 0 or 1 and&#xD;
             living at least 6 months&#xD;
&#xD;
          5. No main organ dysfunction, adequate cardiac,hepatic,renal and bone marrow function&#xD;
&#xD;
          6. Adequate hematologic function (value in center laboratory as the standard); white&#xD;
             blood cell count (WBC)≥4.0×109/L neutrophil count (ANC)≥1.5×109/L; platelet count&#xD;
             (PLT)≥100×109/L; hemoglobin (HGB)≥lOO g/L.&#xD;
&#xD;
          7. Adequate hepatic and renal function(value in center laboratory as the standard):&#xD;
&#xD;
          8. Women of childbearing age need to pregnancy test Prior to receive therapy and agree to&#xD;
             use effective contraception throughout the study&#xD;
&#xD;
          9. Subjects, who are willing to follow the study protocol and provide written informed&#xD;
             consent voluntarily, have understood the purpose and procedures and could follow&#xD;
             requirements of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of cardiopathy or with signs and symptoms&#xD;
&#xD;
          2. History of bone marrow transplant and/or stem cell transplant&#xD;
&#xD;
          3. Patients with acute infection, systemic anti-infection treatment within 72 hours of&#xD;
             study&#xD;
&#xD;
          4. Prior participated in drug therapy, radiotherapy or surgery and other clinical trials&#xD;
             within 4 weeks&#xD;
&#xD;
          5. Prior use of recombinant human G-CSF(rhG-CSF)、PEG-rhG-CSF or erythropoietin within 4&#xD;
             weeks of study&#xD;
&#xD;
          6. Patients with history of primary myeloid malignancy or myelodysplasia&#xD;
&#xD;
          7. Known hypersensitivity to test drugs, rhG-CSF or any other biologicals&#xD;
&#xD;
          8. Pregnant female or nursing mother&#xD;
&#xD;
          9. Known HIV positive or active hepatitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zhongsheng Tong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Cancer Institute and Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>June 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2014</study_first_posted>
  <last_update_submitted>February 22, 2016</last_update_submitted>
  <last_update_submitted_qc>February 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

